LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that its representatives plan to attend MEDICA 2026 in Düsseldorf, Germany, one of the world's largest international healthcare and medical technology trade fairs. The company's participation is intended to support its ongoing evaluation of healthcare technologies, strategic industry relationships, vendor solutions, digital infrastructure initiatives, and broader commercialization opportunities associated with its developing healthcare technology ecosystem.
The company plans to engage with healthcare technology providers, telehealth vendors, pharmaceutical infrastructure participants, medical software developers, AI-focused healthcare companies, and other industry stakeholders operating throughout Europe, Latin America, and additional international markets. Management believes participation in international healthcare industry events may provide opportunities to evaluate emerging technologies, support industry relationship development, and advance the company's long-term digital healthcare infrastructure strategy across Latin America and other developing markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "Healthcare systems around the world are rapidly moving toward technology-driven and AI-enabled infrastructure models. Our attendance at MEDICA reflects our commitment to engaging with industry participants, evaluating emerging technologies, and continuing to build a scalable healthcare platform designed to support long-term digital healthcare modernization initiatives throughout Latin America."
The company remains in the development and commercialization stage with respect to certain aspects of its healthcare technology platform and business operations. It cautions that attendance at industry conferences and trade fairs does not guarantee strategic relationships, commercial agreements, financing arrangements, technology integrations, revenue generation, or future operational success. The company continues to advance telehealth deployment initiatives, healthcare analytics integration, operational scalability planning, strategic relationship development, and broader commercialization efforts associated with its long-term digital healthcare ecosystem strategy throughout Latin America.
This announcement is significant as it highlights LataMed AI Corp.'s proactive approach to engaging with the global healthcare technology community. By attending MEDICA, the company positions itself to identify and evaluate cutting-edge technologies that could be integrated into its platform, potentially accelerating the digital transformation of healthcare delivery in emerging markets. For readers, this suggests that LataMed is actively seeking partnerships and solutions that could improve access to healthcare in underserved regions, which may have broader implications for public health and economic development in Latin America.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
